Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient po... by Simon Dagenais, Christine Lee, Carol Cronenberger, Ellen Wang, Vaishali Sahasrabudhe

Connect to this object online.

Physiologically‐Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid by Ernesto Callegari, Jian Lin, Susanna Tse, Theunis C. Goosen, Vaishali Sahasrabudhe

Connect to this object online.

Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers by Daryl J. Fediuk, Kevin Sweeney, Vaishali Sahasrabudhe, Thomas McRae, Wonkyung Byon

Connect to this object online.

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor by Daryl J. Fediuk, Gianluca Nucci, Vikas K. Dawra, Ernesto Callegari, Susan Zhou, Cynthia J. Musante, Yali Liang, Kevin Sweeney, Vaishali Sahasrabudhe

Connect to this object online.